Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04488016 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate Relative Bioavailability, Proton Pump Inhibitor (PPI) (Rabeprazole) Effect, Food Effect and Particle Size Effect of New Acalabrutinib Tablet in Healthy Subjects
A Phase 1 study of Bioavailability and B-cell Lymphoid Cancer, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 54
- Enrollment target
- 1
- Study location
NCT04488016 is a Phase 1 study of Bioavailability and B-cell Lymphoid Cancer that has completed, run by AstraZeneca. The registered enrollment target is 54 participants, above the 31-participant average among 8 other Bioavailability trials with a reported enrollment target (74% higher). The trial reports 1 study location across 1 state.
The verdict
NCT04488016, a Phase 1 study of Bioavailability and B-cell Lymphoid Cancer, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 54 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will be a 2-part, open-label, single-center relative bioavailability, PPI effect, food-effect and particle size effect randomized crossover study of acalabrutinib tablets in healthy subjects (males or females). The study will be divided in 2 study parts; following a review of the safety and Pharmacokinetics (PK) data from Part 1, the study is planned to be continued with Part 2.
Conditions Studied
Interventions
- DRUG Treatment A- Part 1
- DRUG Treatment B- Part 1
- DRUG Treatment C - Part 1
- DRUG Treatment D- Part 1
- DRUG Treatment A-Part 2
Study Locations (1)
Maryland
- Research Site - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2020-06-24 |
| Est. Completion | 2021-01-20 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04488016
The ClinicalTrials.gov registry entry for NCT04488016 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 31-participant average among 8 other Bioavailability trials with a reported enrollment target (74% higher). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Bioavailability appearing as the primary indexed condition, and to 5 interventions - of which Treatment A- Part 1 is the first listed.
NCT04488016 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT04488016 about?
NCT04488016 is a clinical study titled "A Study to Evaluate Relative Bioavailability, Proton Pump Inhibitor (PPI) (Rabeprazole) Effect, Food Effect and Particle Size Effect of New Acalabrutinib Tablet in Healthy Subjects". This study will be a 2-part, open-label, single-center relative bioavailability, PPI effect, food-effect and particle size effect randomized crossover study of acalabrutinib tablets in healthy subjects (males or females). The study will be divided in 2 study parts; following a review of the safety a...
What is the current status of trial NCT04488016?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 54 participants. The study started on 2020-06-24. Estimated completion is 2021-01-20.
What conditions does trial NCT04488016 study?
This clinical trial studies the following conditions: Bioavailability, B-cell Lymphoid Cancer.
What interventions are being tested in trial NCT04488016?
The interventions under investigation include: Treatment A- Part 1 (DRUG), Treatment B- Part 1 (DRUG), Treatment C - Part 1 (DRUG), Treatment D- Part 1 (DRUG), Treatment A-Part 2 (DRUG).
Who is sponsoring clinical trial NCT04488016?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04488016 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bioavailability
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Curcumin and Retinal Study
RECRUITING · Phase 1
-
A Study of TEPEZZA Subcutaneous Administration in Healthy Adults
COMPLETED · Phase 1
-
Relative Bioavailability Study of PF-07321332/Ritonavir Oral Powder Relative to the Commercial Tablets in Healthy Participants
COMPLETED · Phase 1
-
Pharmacokinetics Study of Oral Rivaroxaban in Healthy Participants
COMPLETED · Phase 1
-
Relative Bioavailability Study of 4 Different Formulations of PF-07321332 Relative to the Commercial Tablet Formulation
COMPLETED · Phase 1
-
Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of Intravenous WCK 771
COMPLETED · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.